Treatment Information

Back

Bladder Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Apr 2013

Description:

Patients:
This phase 2 study involved 45 advanced urothelial carcinoma patients. The median patient age was 66 years and 69% were male.

Treatment:
Patients were treated with the biologic therapy agent everolimus, which is an mTOR inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 fatigue, lung inflammation, and infection.

Results:
The median overall survival was 8.3 months.

Support:
This study was partially supported by Novartis Pharmaceuticals Corporation.

Correspondence: Dr. Matthew I. Milowsky; email: [email protected]



Back